Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FFAR1 | O14842 | 2/20 | 0.41 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.36 |
| ▸ | AR | P10275 | 2/20 | 0.35 |
| ▸ | PPARG | P37231 | 2/20 | 0.34 |
| ▸ | PIK3C3 | Q8NEB9 | 1/20 | 0.33 |
| ▸ | MGLL | Q99685 | 1/20 | 0.33 |
| ▸ | C1R | P00736 | 1/20 | 0.32 |
| ▸ | PPARA | Q07869 | 1/20 | 0.31 |
| ▸ | TNKS | O95271 | 2/20 | 0.31 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.31 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.31 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | GLA | P06280 | 1/20 | 0.31 |
| ▸ | GAA | P10253 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL828012 | 0.89 | FFAR1 (0.38) | FFAR1PDE10AARPIK3C3C1R | |
| SCHEMBL828191 | 0.88 | FFAR1 (0.41) | FFAR1PDE10APIK3C3TNKSL3MBTL1 | |
| SCHEMBL826952 | 0.87 | FFAR1 (0.46) | FFAR1PDE10AARPIK3C3C1R | |
| SCHEMBL827287 | 0.86 | FFAR1 (0.43) | FFAR1PDE10AARPIK3C3C1R | |
| SCHEMBL827978 | 0.85 | FFAR1 (0.42) | FFAR1PDE10AARPIK3C3C1R | |
| SCHEMBL828353 | 0.85 | FFAR1 (0.38) | FFAR1PDE10AARPPARGPIK3C3 | |
| SCHEMBL828352 | 0.85 | FFAR1 (0.38) | FFAR1PDE10AARPPARGPIK3C3 | |
| SCHEMBL827979 | 0.84 | FFAR1 (0.41) | FFAR1PDE10AARPPARGPIK3C3 | |
| SCHEMBL826935 | 0.83 | FFAR1 (0.44) | FFAR1PDE10AARPIK3C3C1R | |
| SCHEMBL828396 | 0.83 | FFAR1 (0.41) | FFAR1PDE10AARPIK3C3C1R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1724262-B1 | 1-(2H)-ISOQUINOLONE DERIVATIVE | CHUGAI PHARMACEUTICAL CO LTD (JP) | 2012-05-02 | — | — | EP | disclosed |
| US-8143274-B2 | 1-(2H)-isoquinolone derivative | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2012-03-27 | — | — | US | disclosed |
| US-20070185160-A1 | 1-(2H)-isoquinolone derivative | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2007-08-09 | — | — | US | disclosed |
| EP-1724262-A1 | 1-(2H)-ISOQUINOLONE DERIVATIVE | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2006-11-22 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070185160-A1 | 1-(2H)-isoquinolone derivative | NR3C2, NR1H4, NR3C1 | FFAR1 452/4885PDE10A 3212/4885AR 254/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.